Un­pack­ing FDA’s lat­est Alzheimer’s OK; A look at all drugs ap­proved in 2022; Mod­er­na’s deal spree; Pfiz­er re­vamps ear­ly re­search; and more

Wel­come back to End­points Week­ly, your re­view of the week’s top bio­phar­ma head­lines. Want this in your in­box every Sat­ur­day morn­ing? Cur­rent End­points read­ers can vis­it their read­er pro­file to add End­points Week­ly. New to End­points? Sign up here.

Sure, deals are what it’s all about at JPM. But I’ll be walk­ing around San Fran­cis­co with a spe­cial ear to what peo­ple say about lecanemab. Hit me with thoughts on the land­mark Alzheimer’s ap­proval — or any oth­er pre­dic­tions for the year to come.

To read Endpoints News become a free subscriber

Unlock this article instantly, along with access to limited free monthly articles and our suite of newsletters

SIGN UP LOG IN